<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03635866</url>
  </required_header>
  <id_info>
    <org_study_id>18-00601</org_study_id>
    <nct_id>NCT03635866</nct_id>
  </id_info>
  <brief_title>PET/MRI Study of Men With Highly Suspicious MRI Lesions That Showed no Clinically Significant Prostate Cancer Following MRI Fusion Targeted Biopsy</brief_title>
  <official_title>PET/MRI Study of Men With Highly Suspicious MRI Lesions That Showed no Clinically Significant Prostate Cancer Following MRI Fusion Targeted Biopsy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NYU Langone Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NYU Langone Health</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The principal aim of this study is to determine if PET/MRI imaging with 18-F fluciclovine
      (Axumin) identifies those men with false negative MRI fusion targeted biopsy (MRFTB) of
      PI-RADS 4 and 5 lesions. PI-RADS 4 and 5 MRI lesions are highly suspicious for clinically
      significant prostate cancer and require future repeat MRI imaging and possible repeat
      prostate biopsy depending on the results of the repeat MRI. Men, who had negative MRFTB
      within past 12 months of PI- RADS 4 or 5 MRI lesion will be included in this diagnostic
      study. The repeat MRI is standard of care at NYU Langone Health. The investigation aspect of
      the study is to perform an Axumin scan the same day as the MRI. Those men with persistent
      highly suspicious lesions will under MRFTB. The biopsy results will be compared with
      intensity of Axumin uptake within the prostate. The urologist will have the discretion to
      biopsy Axumin avid lesions not detected by MRI.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 2, 2019</start_date>
  <completion_date type="Anticipated">January 2, 2021</completion_date>
  <primary_completion_date type="Anticipated">January 2, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with negative prostate biopsy</measure>
    <time_frame>12 Months</time_frame>
    <description>This will be measured by determining is if PET imaging with 18-F fluciclovine (Axumin) identifies those men with prior negative MRFTBs of PI-RADS 4 and 5 lesions who harbor clinically significant prostate cancer</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>prior negative MRFTB of PI-RADS 4 and 5 lesions</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Diagnosed withing 12 months of initial diagnostic cancer biopsy</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Fluciclovine PET/MRI</intervention_name>
    <description>It is unknown how many negative MRFTBs of PI-RADS 4 lesions are false negative biopsies or false positive tests.</description>
    <arm_group_label>prior negative MRFTB of PI-RADS 4 and 5 lesions</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The participant has undergone MRFTB of an MRI lesion at the Department of Urology or
             at NYU Langone Health within past 12 months and has signed informed consent to
             participate in the NYU Urology prostate biopsy database.

          -  The most recent MRFTB of a PIRADS 4 or 5 lesion did not show clinically significant
             prostate cancer.

        Exclusion Criteria:

          -  The urologist who performed the initial MRFTB does not feel a repeat MRI is indicated.

          -  Any contraindication to prostate biopsy including untreated urinary tract infection

          -  Prior allergic reaction to axumin

          -  Patient refuses MRI
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Herbert Lepor, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NYU Langone Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rozalba Gogaj</last_name>
    <phone>646-825-6356</phone>
    <email>Rozalba.Gogaj@nyulangone.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Herbert Lepor, MD</last_name>
    <phone>646 825 6340</phone>
    <email>Herbert.Lepor@nyulangone.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>New York University Langone Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rozalba Gogaj</last_name>
      <phone>646-825-6356</phone>
      <email>Rozalba.Gogaj@nyulangone.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>August 15, 2018</study_first_submitted>
  <study_first_submitted_qc>August 15, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 17, 2018</study_first_posted>
  <last_update_submitted>January 9, 2020</last_update_submitted>
  <last_update_submitted_qc>January 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>The objective of the study is: to determine if PET imaging with 18-F fluciclovine identifies those men with prior negative MRFTBs of PI-RADS 4&amp;5</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

